Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Friday, October 9, 2026

Back to today

From X

@calvinblissett 1 click

Calvin Blissett on X

This is a piece by @MagicCompounds $PAL. Quick Glance 4x LTM FCF with synergies coming from March acquisition. PAL consolidated at bottom of cycle (now largest player) and cycle is showing tell-tale signs of rationalization (bankruptcy of 2nd largest player) Positives and Negatives: Highly regarded CEO in the industry who has done this before with high returns (+), getting hurt by diesel (-), should catch up due to mechanism and incentives to continue providing service, current Q may be ugly especially GAAP. Consolidated at bottom of cycle (+). Lots of leverage provides torque and risk (+/-), double the insider sales to purchases (-). 15% market cap buyback with barely any used (-).
@StableBread

Fajasy on X

At ~$6.8M net of cash, Nubeva Technologies $NBVAF (TSXV: $NBVA) trades below every one of the five small ransomware-security deals I found with a disclosed price. That’s a CAD$13.0M market cap at CAD$0.185/share (70,173,783 × CAD$0.185), or $9.3M at 1.40 USD/CAD, with the $2.49M of cash and $12,262 of debt netted out. The $6.8M buys two granted patents, two pending applications, the unfinished AI decryptor builder, and a deployment agreement with what Nubeva calls a top-10 global bank, on $500,586 of FY2026 revenue. Here’s what larger security firms paid for five small companies that detect, stop, or recover from ransomware, per the buyers’ filings: → Smokescreen (June 2021): Zscaler $ZS paid ~$11.7M in cash for a startup that plants decoys to catch attackers. → TrapX Security (January 2022): Commvault $CVLT paid $18.65M in cash for an Israeli decoy-technology company. → Minerva Labs (March 2023): Rapid7 $RPD paid $34.6M for a 14-person Israeli startup selling anti-evasion and ransomware-prevention software. → Appranix (April 2024): Commvault paid $26.27M in cash and stock for a Boston startup that cuts the time to rebuild cloud applications after an attack. → Airgap Networks (April 2024): Zscaler paid $124.4M for an “early-stage” network-security company whose product it called a “ransomware kill switch.” For context, Commvault bought TrapX and Appranix as product lines already bringing in ~$3.2M and ~$2.4M a year. Rapid7 and Zscaler bought Minerva Labs and Airgap mainly for their technology. A buyer would be paying for Nubeva’s technology too, meaning four AI patents (assuming the last two come through), the key-capture agent, and a top-10 bank as a reference account (if the license customer renewed), not just ~$500K of revenue. Still, Nubeva’s revenue is a fifth or less of what TrapX and Appranix brought in, and 82% of its revenue comes from two customers, one of which may not have renewed. So I’d put a sale at the low end of these deals, $12-19M (Smokescreen to TrapX), or CAD$0.23-0.37/share, 1.3-2.0x from here. The ~$26M median (2.8x) is the more bullish upside case. If nothing works, two more years of burn leave $0.93-1.29M of cash, and adding the two granted patents and what’s left of the business gets shareholders $1.33-2.01M, or CAD$0.03-0.04/share, a 78-86% loss from CAD$0.185. In other words, CAD$0.185 sits ~45% of the way between the CAD$0.03-0.04 floor and a TrapX-size sale (CAD$0.37/share). If those are the only two outcomes, the market is pricing a sale as close to a coin flip.
@stockgutter

SG on X

$WQEY $SAIQ $LAES $GIW agree to a Rube Goldberg de-SPAC transaction. According to the headline, the purpose is to have Quantismo "become a Nasdaq-listed public company." But, facts. Quantismo is already owned by two public companies, SealsQ and WiseQey. They could simply spin it out to shareholders. As far as I can tell, Quantismo has no meaningful revenue or operations of its own and is simply a holdco for unserious investments in the sector, including (as part of this transaction) a healthy dollop of shitco WiseSat .space (SAIQ). This isn't a private to public transaction. It's a shell game between four existing pubcos. I suspect that retail investors are the marks.
@convequity

Convequity on X

Software multiples have fallen further since our January report. As of 7 Oct 2026, 238 companies in our all-software watchlist have EV/Sales (NTM) data on Koyfin. The median is 3.1x, down from 3.7x in January. The average is 5.4x, down from 6.2x. The 25th percentile is 1.8x, down from 1.9x. The 75th percentile is 5.5x, down from 6.1x. 191 of the 238 (80%) trade below our 6.7x private equity floor. 113 trade below 3x. The Bessemer Cloud Index shows the same pattern. Its median is 4.7x, down from 5.1x in January. 46 of its 68 companies (68%) trade below 6.7x. The cheapest are $CXM at 0.9x, $SPT at 1.1x, $MNDY at 1.7x and $WIX at 1.8x. In our watchlist, only 21 companies trade above 10x. The most expensive are $PLTR at 44.5x, $CRWD at 42.4x, $NET at 38.6x, $PANW at 24.2x, $DDOG at 19.5x and $SNOW at 16.3x. Growth still earns a higher multiple. The 44 names expected to grow revenue 20%+ a year over 3 years have a median of 5.2x. The 85 names expected to grow under 10% have a median of 2.6x. Even for the faster growers, the 5.2x median is below the floor. The market is paying up for very few names. We think that is right. Many software companies have slowing growth, high costs and no clear AI strategy. We would not buy the sector, or a cloud index, on valuation alone. In software, we focus on the few companies rebuilding their products around AI, and our SaaS Survival Scorecard tests key SaaS names against the pressure from AI agents.

Investor Letters

All letters

What I’ve Been Up To

Cogent Communications and AI data-center bottlenecks feature in a newsletter update on recruiting, financial media and conference takeaways.

CCOI $515M
Stock Thoughts 2 clicks

Not So Fast

Entravision, the portfolio’s largest position, fell more than 40% from its highs as Q3 returns dropped to 37.8% YTD.

EVC $634M
The Mikro Kap 1 click

Zentek Research Note

Zentek shipped its first ZenGUARD air-filter order to a Canadian federal facility as its Albany graphite PEA confirmed a US$3.85 billion…

ZTEKF $58M
Atrium Research - Equity Research 1 click
LWAY · long

Lifeway Foods INC

Lifeway Foods holds 95% market share in kefir, is growing 20% to 35%, and trades at 12 times projected 2027 earnings as its capex cycle…

LWAY $320M
Value Investors Club

Notes and Updates

ECIP recipient banks could repurchase Treasury preferred shares at steep discounts, potentially lifting book value, while Hawaiian Electric…

UBAB $186M
Exploring with Alluvial Capital

Mereo Biopharma

Mereo Biopharma has two late-stage assets, seeks non-dilutive financing for alvelestat Phase 3 trials, and reports cash runway through 2027.

MREO $56M
Raging Bull Investments

JBG Smith

JBG Smith trades at an estimated 40% discount to NAV, backed by National Landing multifamily assets, Amazon HQ demand and $1.3 billion of…

JBGS $813M
Raging Bull Investments

IOFNF- Iofina (buy)

Iofina’s IO10 iodine plant is due in Q3 2024, adding 100 to 150 metric tons of capacity while higher brine costs pressure earnings.

IOFNF $107M
Sylence Capital

Publications we follow

Every publication on this site, hand-picked.

109 publications

Newsletters 92

YouTube 4

Blogs 12

Seeking Alpha 46 of 218

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

74 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.